Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Specialty pharmaceutical company Uluru has said that Meldex International has filed the regulatory dossier for approval of Uluru's proprietary product OraDisc B in Europe. OraDisc B incorporates 15 milligrams of benzocaine for the treatment of oral pain.
Subscribe to our email newsletter
Under the terms of the agreement this will trigger a major milestone payment from Meldex International in February 2008.
Kerry Gray, president and CEO of Uluru, said: “I am very pleased with the progress Meldex has made preparing and submitting the OraDisc B Dossier. Securing a regulatory approval for our adhesive film technology in Europe is an important step in our overall commercialization strategy for this technology.”